Skip Ribbon Commands
Skip to main content

Current Clinical Trials

For enquiries, please email

Phase 1

No Site​ ​Stage of cancer Title of study ​Principal investigator ​Details of trial ​Status
​1Pancreas​​Adv 2nd/3rd line

Phase I trial of OXIRI [oxaliplatin (O), xeloda (X) and irinotecan (I)]  treatment in patients with advanced and/or metastatic pancreatic adenocarcinoma

​Dr Matthew Ng NCT02368860​Open
​2​All Solid Tumour​IVD3-002
A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours
​​Dr Matthew Ng NCT02521844​On hold
​3​All Solid Tumour​FGFR expressions and  fusionDebio 1347-101
A phase I, gene alteration-based, open label, multicenter study of oral Debio 1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes
​Dr Matthew Ng NCT01948297​Open
A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy
​Dr Yap Yoon Sim NCT02734615​Open
​5​All Solid Tumour​IVCPDR001X2103
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib)
​Dr David Tai NCT02900664​Open
​6​All Solid Tumour​IVCMAK683X2101
A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
​Dr Daniel Tan NCT02900651​Open
​7​All Solid Tumour​IVCBLZ945X2101
A Phase I/II, open-label, multi-center of the safety and efficacy of BZL945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors malignancies.
​Dr Darren Lim NCT02829723​Open
​8​Ovarian, tubal or peritoneal origin epithelial cancer​RecurrentORION-01 / NCCOV-02
Prospective Phase Ib-II clinical trial to evaluate the safety and activity of Oregovomab and Nivolumab as a combinatorial immunotherapy strategy in patients with recurrent epithelial cancer of ovarian, tubal or Peritoneal Origin
​Dr Jack Chan NCT03100006​On hold
​9​All Solid Tumour​IVCTNO155X2101
An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors
​​Dr Daniel Tan NCT03114319​Open
​10​CRC and PDAC​AdvancedCTMT212XSG01T
Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma
​Dr David Tai​Pending​Open
Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients
​Dr Daniel Tan NCT03064854​Open
​12​All Solid Tumour​IV15834
Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies
​Dr Matthew Ng NCT03102320​Open
​13​All Solid Tumourdocumented RET infusionLOXO-RET-17001
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
​Dr Daniel Tan NCT03157128​Open
​14​Non-small cell lung cancer​IVCEGF816X2102
A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC
​Dr Daniel Tan NCT03333343​Open
​15​All Solid Tumourdocumented RET infusionBLU-667-1101
A Phase 1 Study of the Highly-selective RET inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumours
​​Dr Daniel Tan NCT03037385​Open
​16​Non-small cell lung cancer​IVMCLA-128-CL01
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
​Dr Justina Lam NCT02912949​Open
​17​All Solid Tumour with documented NTRK fusions ​must had prior TRK inhibitorLOXO-EXT-17005
A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers
​Dr Daniel Tan NCT03215511​Open
​18​All Solid Tumour​IVCNZV930X2101
A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies
​Dr David Tai NCT03549000​Open
​19​All Solid Tumour​IVBAY 1163877 / 19774
A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, locally advanced or metastatic solid tumors
​Dr Justina Lam NCT03517956​Open
​20​Pancreatic​not more than 2 prior linesB9991033
A Phase 1b/2 study to evaluate safety and clinical activity of avelumab in combination with Binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumors
​Dr Daniel Tan NCT03637491​On hold
​21​​All Solid Tumour​with documented ATM lossBAY 1895344 / 18594
An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas
​Dr Daniel Tan NCT03188965​Open
​22​BreastTNBC, not more than 2 prior lines of chemotherapy. Neoadjuvant or adjuvant chemotherapy will count as one prior line.CADPT01A12101C
A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer
​Dr Jack Chan NCT03742349​Open
​23​NSCLC​Advanced recurrentBI 1200.275
A dose finding study of continuous and intermittent high-dose (HDI) Afatinib (EGFR Tyrosine Kinase Inhibitor) on CNS metastases and leptomeningeal disease (LMD) in patients with advanced refractory EGFR mutation positive non-small cell lung cancer
​Dr Daniel Tan NCT03711422​Open
​24​All Solid Tumour​FGFR fusions

Debio 1347-201 

A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3                                                                            

​Dr Matthew Ng NCT03834220​Open
​25​Liver​IV D4191C00022                                                                                   A Safety and Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma ​Dr David Tai​NA​Open

Current clinical trials by body parts

No Site​ ​Stage of cancer ​Title of study ​Principal investigator Details of trial Status
Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine + Cisplatin for Intra-hepatic Cholangiocarcinoma
​​Dr David Tai​NA​Open
​2​Bladder​Unresectable or Metastatic Urothelial CancerCA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
​Dr Ravindran Kanesvaran NCT03036098​Open
​3​Bladder​FGFR-positive locally advanced or metastatic urothelial carcinoma17403
A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.
​Dr Toh Chee Keong NCT03410693​On hold
​4​Breast​STAGE 4, BRAIN METS, 2nd LINE, HER2 +ASLAN001-006
A phase II single arm trial to assess the efficacy of ASLAN001 plus capecitabine in previously irradiated, progressing central nervous system (CNS) metastases for HER2 positive breast cancer patients.
​Dr Lee Guek Eng​NA​Open
​5​Breast​HER2-, Hormone Receptor +, Advanced Breast CaCBYL719X2402 (BYLIEVE)
A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
​Dr Yap Yoon Sim NCT03056755​Open
​6​Breast​LA or MBC TNBC and HR(+) HER2 (-), 1st Line for LA/MBCCO40016
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/ AKT1/ PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
​Dr Rebecca Dent NCT03337724​Open
​7​Breast​Inoperable LA/MBC, TNBCMO39193
Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy in Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer
​​Dr Rebecca Dent NCT03371017​Open

Hormone Receptor+,

SYD985.002 (TULIP)
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2- positive unresectable locally advanced or metastatic breast cancer
Dr Jack Chan​ NCT03262935​Open
​9​Breast​HR (ER and/or PgR) positive , MBCODO-TE-B301
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane.
​Dr Elaine Lim NCT03326674​Open

1st or 2nd line

A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer
​Dr Rebecca Dent NCT03499899​Open
​11​Breast​Inoperable LA/MBC, TNBCDORA
Phase II Multicenter Study of Olaparib or Olaparib and MEDI 4736 in Platinum Treated Triple Negative Breast Cancer
​Dr Rebecca Dent NCT03167619​Open
​12​Breast​premenopausal perimenopausal 
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study
​Dr Yap Yoon Sim NCT03839823​Open
​13​CRC​NeoadjuvantOTSP-WoOCRC / MK-3475-886
Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer
​Dr Iain Tan NCT03984578​Open
Aspirin For Dukes C And High Risk Dukes B Colon Cancer – An International Multi-Centre, Double Blind, Randomized Placebo Controlled Phase III Trial     
​Dr Tham Chee Kian NCT00565708​Open
Gastroesophageal Junction
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
​Dr Matthew Ng NCT03221426​Open
Gastroesophageal Junction
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
​Dr Matthew Ng NCT02743494​Open
A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy
​Dr Matthew Ng NCT03427814​Open
Gastroesophageal Junction
​Advance 1st lineCA224-060
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
​​Dr Matthew Ng NCT03662659​Open
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer (EORTC-1203-GITCG)
​​​Dr Matthew Ng NCT02205047​Open
​20​GIST​Locally Advanced Unresectable/ MetastaticBLU-285-1303
An International Multi-Centre Open-Label, Randomized, Phase 3 Study of BLU 285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST).
​Dr Nagavalli NCT03465722​Open
​21​GIST​Locally Advanced / MetastaticDCC-2618-03-002
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
​Dr Nagavalli NCT03673501​Open
​22​Ovarian​Recurrent, AdvancedGY02/06/16
A Multicentre Phase II randomised trial of Durvulamab (MEDI4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas (MOCCA)
​Dr Chay Wen Yee NCT03405454​Open
​23​Nasopharyngeal​LOCALLY RECURRENT  / METASTATIC - 2nd LINECA209-796:
A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma
​Dr Darren Lim NCT03097939​On hold
​24​Nasopharyngeal​T3-T4 disease without distant metastasisMISSION16:
18F-FMISO PET guided dose escalation in nasopharyngeal carcinoma – a feasibility and planning study
​Dr Kiattisa Sommat​NA​Open
​25​Nasopharyngeal​Neoadjuvant / Stage IVANEO-SPACE
Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer
​Dr Darren Lim NCT03734809​Open
Phase III, Randomized, Placebo-Controlled, Multicenter, Double-Blind Study Comparing JS001 Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer
​Dr Darren Lim NCT03581786​Open
A Phase II Open-label, Single Centre, Non-randomized Trial of Y90-Radioembolization in combination with Nivolumab in Asian Patients with Advanced Hepatocellular Carcinoma.
​Dr David Tai NCT03033446​On hold
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
​Dr David Tai NCT03383458​Open
A phase II, multicenter, three-cohort of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/ metastatic disease
​Dr Ang Mei Kim NCT02414139​Open
​30​Lung​ADVANCED/ METASTATIC -2nd LINE and aboveCA209-777
Randomised phase 2 study of nivolumab versus nivolumab and ipilimumab combination in EGFR mutant Non-small Cell Lung Cancer
​Dr Tan Eng Huat NCT03091491​Open
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
​Dr Daniel Tan NCT03178552​Open
​32​Lung​LOCALLY ADVANCED/ METASTATIC - First LineMK-3475-495
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
​Dr Daniel Tan NCT03516981​Open
A Phase III, Open-label, Randomized Study to Evaluate the Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage IB (Tumors ≥ 4 cm) to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (ALINA)
​Dr Toh Chee Keong NCT03456076​Open
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2)
​Dr Darren Lim NCT03626545​Open
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects
​Dr Tan Wan Ling NCT03631199​Open
​36​Lymphoma​RELAPSEDBayer 17833
A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard mmunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4
​Dr Lim Soon Thye NCT02626455​Open
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Flurouracil plus Cisplatin versus Platinum Doublet Chemotherapy in Subjects with Inoperable Locally Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
​Dr Matthew Ng NCT03143153​Open
​38​Renal​Resectable Renal CancerCA209-914
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
​Dr Ravindran Kanesvaran NCT03138512​Open


​No Site​ ​Stage of cancer ​Title of study ​Principal investigator ​Details of trial ​Status
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
​Dr Daniel Tan NCT02584933​Open
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
​Dr Daniel Tan NCT02576431​Open
An Open-label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements 
​Dr Daniel Tan NCT02568267​Open
An Open-label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, An Immunocytokine, Consisting of Interleukin-2 Variant (IL-2V) Targeting Fibroblast Activation Protein-A (FAP), in Combination with Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants with Advanced and/or Metastatic Solid Tumors
​Dr Darren Lim NCT03386721​On hold
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 848)
​Dr Iain Tan NCT03668119​Open
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma
​Dr Daniel Tan NCT03207867​Open